[ad_1]
LSK Global Pharma Service (LSK Global PS) signed a memorandum of understanding (MOU) for joint clinical development cooperation for a new coronavirus infection (Corona 19) clinical trial between Daewoong Pharmaceutical and Hoy Star Tablet (ingredient name Camostat mesylate ) on the 21. concluded.
This MOU was concluded to cooperate with Hoystar Tablet’s involvement in the clinical development of COVID-19 treatment, share staff and infrastructure for clinical trials, and establish clinical strategies.
Through the signing of the MOU, LSK Global PS performs tasks throughout clinical trials, including follow-up, clinical trial operation, data management, and statistics.
The two companies plan to cooperate on strategies and development directions to expand global clinical trials not only in Korea but also abroad.
Today Star Tablet is a drug developed by Daewoong Pharmaceutical as Corona 19 oral treatment through drug recreation. Daewoong Pharmaceutical has started large-scale phase 2/3 clinical trials for patients and plans to conduct prophylactic clinical trials.
Daewoong Pharmaceutical Chairman Seung-ho Jeon said: “Hoi Star Tablet is a drug that can be used in a wide range of patients and we hope it will contribute greatly to overcoming the global COVID-19 pandemic.” provide Corona 19 treatment to patients in the near future. “
LSK Global PS CEO Lee Young-jak said: “It is significant that LSK Global PS can contribute to the end of Corona 19 by being in charge of Corona 19 related clinical trials from Daewoong Pharmaceutical, including Hoy Star.” “This time with a sense of mission to surpass Corona 19 quickly” We will do our best to quickly and successfully complete the Corona 19 clinical trial of Hoy Star from Daewoong Pharmaceutical. “
